Top

Published in:

01-06-2008 | Original Article

Tumor-derived death receptor 6 modulates dendritic cell development

Authors: David C. DeRosa, Paul J. Ryan, Angela Okragly, Derrick R. Witcher, Robert J. Benschop

Published in: Cancer Immunology, Immunotherapy | Issue 6/2008

Abstract

Studies in murine models of cancer as well as in cancer patients have demonstrated that the immune response to cancer is often compromised. This paradigm is viewed as one of the major mechanisms of tumor escape. Many therapies focus on employing the professional antigen presenting dendritic cells (DC) as a strategy to overcome immune inhibition in cancer patients. Death receptor 6 (DR6) is an orphan member of the tumor necrosis factor receptor superfamily (TNFRSF21). It is overexpressed on many tumor cells and DR6^−/− mice display altered immunity. We investigated whether DR6 plays a role in tumorigenesis by negatively affecting the generation of anti-tumor activity. We show that DR6 is uniquely cleaved from the cell surface of tumor cell lines by the membrane-associated matrix metalloproteinase (MMP)-14, which is often overexpressed on tumor cells and is associated with malignancy. We also demonstrate that >50% of monocytes differentiating into DC die when the extracellular domain of DR6 is present. In addition, DR6 affects the cell surface phenotype of the resulting immature DC and changes their cytokine production upon stimulation with LPS/IFN-γ. The effects of DR6 are mostly amended when these immature DC are matured with IL-1β/TNF-α, as measured by cell surface phenotype and their ability to present antigen. These results implicate MMP-14 and DR6 as a mechanism tumor cells can employ to actively escape detection by the immune system by affecting the generation of antigen presenting cells.

Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252PubMedCrossRef

Pulendran B, Palucka K, Banchereau J (2001) Sensing pathogens and tuning immune responses. Science 293:253–256PubMedCrossRef

Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848PubMedCrossRef

Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in the tumor microenvironment. J Immunother 29:233–240PubMedCrossRef

Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147PubMedCrossRef

Steinman RM, Nussenzweig MC (2002) Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99:351–358PubMedCrossRef

Esche C, Lokshin A, Shurin GV et al (1999) Tumor’s other immune targets: dendritic cells. J Leukoc Biol 66:336–344PubMed

Aalamian M, Pirtskhalaishvili G, Nunez A et al (2001) Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46:68–75PubMedCrossRef

Katsenelson NS, Shurin GV, Bykovskaia SN et al (2001) Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mod Pathol 14:40–45PubMedCrossRef

10.

Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487–501PubMedCrossRef

11.

Pan G, Bauer JH, Haridas V et al (1998) Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 431:351–356PubMedCrossRef

12.

Liu J, Na S, Glasebrook A et al (2001) Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice. Immunity 15:23–34PubMedCrossRef

13.

Zhao H, Yan M, Wang H et al (2001) Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med 194:1441–1448PubMedCrossRef

14.

Schmidt CS, Liu J, Zhang T et al (2003) Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. J Exp Med 197:51–62PubMedCrossRef

15.

Kasof GM, Lu JJ, Liu D et al (2001) Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene 20:7965–7975PubMedCrossRef

16.

Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657–672PubMedCrossRef

17.

Seiki M (2003) Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 194:1–11PubMedCrossRef

18.

Tam EM, Morrison CJ, Wu YI et al (2004) Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci U S A 101:6917–6922PubMedCrossRef

19.

Sato H, Takino T, Okada Y et al (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61–65PubMedCrossRef

20.

Sounni NE, Devy L, Hajitou A et al (2002) MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. Faseb J 16:555–564PubMedCrossRef

21.

Chang CC, Wright A, Punnonen J (2000) Monocyte-derived CD1a+ and CD1a− dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation. J Immunol 165:3584–3591PubMed

22.

O’Garra A (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275–283PubMedCrossRef

23.

de Jong EC, Smits HH, Kapsenberg ML (2005) Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol 26:289–307PubMedCrossRef

24.

Kapsenberg ML (2003) Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3:984–993PubMedCrossRef

25.

Rovere-Querini P, Capobianco A, Scaffidi P et al (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5:825–830PubMedCrossRef

26.

Dumitriu IE, Baruah P, Valentinis B et al (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174:7506–7515PubMed

27.

Prechtel AT, Steinkasserer A (2007) CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch Dermatol Res 299:59–69PubMedCrossRef

28.

Laguens G, Coronato S, Laguens R et al (2002) Human regional lymph nodes draining cancer exhibit a profound dendritic cell depletion as comparing to those from patients without malignancies. Immunol Lett 84:159–162PubMedCrossRef

29.

Polak ME, Johnson P, Di Palma S et al (2005) Presence and maturity of dendritic cells in melanoma lymph node metastases. J Pathol 207:83–90PubMedCrossRef

30.

Cochran AJ, Huang RR, Lee J et al (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659–670PubMedCrossRef

31.

Randolph GJ, Angeli V, Swartz MA (2005) Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5:617–628PubMedCrossRef

32.

Ishigami S, Natsugoe S, Uenosono Y et al (2003) Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. J Gastrointest Surg 7:735–739PubMedCrossRef

33.

Iyoda T, Shimoyama S, Liu K et al (2002) The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 195:1289–1302PubMedCrossRef

34.

Liu K, Iyoda T, Saternus M et al (2002) Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196:1091–1097PubMedCrossRef

35.

Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761PubMed

36.

Ormandy LA, Hillemann T, Wedemeyer H et al (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65:2457–2464PubMedCrossRef

37.

Larmonier N, Marron M, Zeng Y et al (2007) Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 56:48–59PubMedCrossRef

38.

Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352PubMedCrossRef

39.

Fisson S, Darrasse-Jeze G, Litvinova E et al (2003) Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med 198:737–746PubMedCrossRef

40.

Whiteside TL, Stanson J, Shurin MR et al (2004) Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 173:1526–1534PubMed

41.

Kim R, Emi M, Tanabe K (2005) Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 4:924–933PubMedCrossRef

42.

Allavena P, Piemonti L, Longoni D et al (1998) IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 28:359–369PubMedCrossRef

43.

Buelens C, Verhasselt V, De Groote D et al (1997) Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol 27:756–762PubMedCrossRef

Title: Tumor-derived death receptor 6 modulates dendritic cell development
Authors: David C. DeRosa
Paul J. Ryan
Angela Okragly
Derrick R. Witcher
Robert J. Benschop
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0413-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2008

Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation

Dendritic cell vaccination and other strategies to tip the balance of the immune system

Dendritic cell vaccination and other strategies to tip the balance of the immune system

Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update

CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells

Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer